BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 37569479)

  • 1. T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.
    Gutierrez M; Bladek P; Goksu B; Murga-Zamalloa C; Bixby D; Wilcox R
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B and T cell prolymphocytic leukaemia.
    Cross M; Dearden C
    Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances and Perspectives in the Treatment of T-PLL.
    Braun T; von Jan J; Wahnschaffe L; Herling M
    Curr Hematol Malig Rep; 2020 Apr; 15(2):113-124. PubMed ID: 32034661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature.
    Gjelberg HK; Helgeland L; Liseth K; Micci F; Sandnes M; Russnes HG; Reikvam H
    Curr Oncol; 2023 Nov; 30(11):10007-10018. PubMed ID: 37999147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
    Staber PB; Herling M; Bellido M; Jacobsen ED; Davids MS; Kadia TM; Shustov A; Tournilhac O; Bachy E; Zaja F; Porkka K; Hoermann G; Simonitsch-Klupp I; Haferlach C; Kubicek S; Mayerhoefer ME; Hopfinger G; Jaeger U; Dearden C
    Blood; 2019 Oct; 134(14):1132-1143. PubMed ID: 31292114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
    Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T
    Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.
    Johansson P; Klein-Hitpass L; Röth A; Möllmann M; Reinhardt HC; Dührsen U; Dürig J
    Eur J Haematol; 2020 Dec; 105(6):786-796. PubMed ID: 32875608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene.
    Sun S; Fang W
    Biomed Pharmacother; 2020 Jun; 126():110107. PubMed ID: 32247279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
    Dholaria BR; Ayala E; Sokol L; Nishihori T; Chavez JC; Hussaini M; Kumar A; Kharfan-Dabaja MA
    Leuk Res; 2018 Apr; 67():1-5. PubMed ID: 29407180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation.
    Yamasaki S; Nitta H; Kondo E; Uchida N; Miyazaki T; Ishiyama K; Kiyota M; Matsuoka H; Ichinohe T; Fukuda T; Atsuta Y; Suzumiya J; Suzuki R
    Ann Hematol; 2019 Sep; 98(9):2213-2220. PubMed ID: 31327025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy.
    Hu Z; Li S; Medeiros LJ; Sun T
    Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.
    Oberbeck S; Schrader A; Warner K; Jungherz D; Crispatzu G; von Jan J; Chmielewski M; Ianevski A; Diebner HH; Mayer P; Kondo Ados A; Wahnschaffe L; Braun T; Müller TA; Wagle P; Bouska A; Neumann T; Pützer S; Varghese L; Pflug N; Thelen M; Makalowski J; Riet N; Göx HJM; Rappl G; Altmüller J; Kotrová M; Persigehl T; Hopfinger G; Hansmann ML; Schlößer H; Stilgenbauer S; Dürig J; Mougiakakos D; von Bergwelt-Baildon M; Roeder I; Hartmann S; Hallek M; Moriggl R; Brüggemann M; Aittokallio T; Iqbal J; Newrzela S; Abken H; Herling M
    Blood; 2020 Dec; 136(24):2786-2802. PubMed ID: 33301031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
    Jain P; Aoki E; Keating M; Wierda WG; O'Brien S; Gonzalez GN; Ferrajoli A; Jain N; Thompson PA; Jabbour E; Kanagal-Shamanna R; Pierce S; Alousi A; Hosing C; Khouri I; Estrov Z; Cortes J; Kantarjian H; Ravandi F; Kadia TM
    Ann Oncol; 2017 Jul; 28(7):1554-1559. PubMed ID: 28379307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delineation of clinical course, outcomes, and prognostic factors in patients with T-cell prolymphocytic leukemia.
    Rose A; Zhang L; Jain AG; Poovathukaran Babu A; Sokol L; Saeed H; Mo Q; Fan W; Zhang X
    Am J Hematol; 2023 Jun; 98(6):913-921. PubMed ID: 36964941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.
    Hu Z; Medeiros LJ; Xu M; Yuan J; Peker D; Shao L; Tang Z; Mai B; Thakral B; Rios A; Hu S; Wang W
    Am J Clin Pathol; 2023 Apr; 159(4):325-336. PubMed ID: 36883805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
    Andersson EI; Pützer S; Yadav B; Dufva O; Khan S; He L; Sellner L; Schrader A; Crispatzu G; Oleś M; Zhang H; Adnan-Awad S; Lagström S; Bellanger D; Mpindi JP; Eldfors S; Pemovska T; Pietarinen P; Lauhio A; Tomska K; Cuesta-Mateos C; Faber E; Koschmieder S; Brümmendorf TH; Kytölä S; Savolainen ER; Siitonen T; Ellonen P; Kallioniemi O; Wennerberg K; Ding W; Stern MH; Huber W; Anders S; Tang J; Aittokallio T; Zenz T; Herling M; Mustjoki S
    Leukemia; 2018 Mar; 32(3):774-787. PubMed ID: 28804127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell Prolymphocytic Leukemia.
    Sud A; Dearden C
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):273-283. PubMed ID: 28340878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Successful Treatment of T-Cell Prolymphocytic Leukemia with Alemtuzumab].
    Ueki D; Yoshida C; Tsutsumi Oota I; Seki M; Komeno T; Ito H; Ide Y
    Gan To Kagaku Ryoho; 2019 May; 46(5):913-915. PubMed ID: 31189814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Durable remission of T-cell prolymphocytic leukemia with CLEC16A::IL2 after allogeneic hematopoietic stem cell transplantation].
    Momose H; Kurita N; Nishikii H; Yusa N; Yokoyama K; Shimizu E; Imoto S; Nanmoku T; Maruyama Y; Sakamoto T; Yokoyama Y; Kato T; Matsuoka R; Obara N; Sakata-Yanagimoto M; Chiba S
    Rinsho Ketsueki; 2024; 65(1):35-40. PubMed ID: 38311387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia.
    Johansson P; Klein-Hitpass L; Choidas A; Habenberger P; Mahboubi B; Kim B; Bergmann A; Scholtysik R; Brauser M; Lollies A; Siebert R; Zenz T; Dührsen U; Küppers R; Dürig J
    Blood Cancer J; 2018 Jan; 8(1):11. PubMed ID: 29352181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.